NCT06244225View on ClinicalTrials.gov

HAIC (Hepatic Artery Infusion Chemotherapy，HAIC）Plus Sintilimab and Donafenib in the First-line Treatment of Unresectable Hepatocellular Carcinoma

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 1, 2024

Primary Completion Date

January 1, 2026

Study Completion Date

January 1, 2028

Conditions

Hepatocellular Carcinoma

Interventions

DRUG

Donafenib； Sintilimab； HAIC

"Drug: Sintilimab Q3W 200mg IV d1, Q3W~Drug: Donafenib 200 mg BID d1-21, Q3W~other: HAIC Q3W Oxaliplatin: 85mg/m2 , Day 1 Leucovorin: 200mg/m2, Day 1 Fluorouracil: 400mg/m2, Day1 and 2400mg/m2 continuous arterial perfusion for 46h."

Trial Locations (1)

Unknown

RECRUITING

Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan

All Listed Sponsors

lead

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

OTHER